Related Experiment Video
Updated: Jul 13, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database
Jialun Zhou1, Gregory J Dore, Fujie Zhang
1National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia.
Insights
Hepatitis B (HBV) and C (HCV) coinfection with HIV affects approximately 10% of patients in the Asia-Pacific region. Coinfection did not significantly impact antiretroviral therapy response but was linked to elevated liver enzymes.
Area of Science:
- Infectious Diseases
- Hepatology
- Virology
Background:
- Limited data exists on hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection in HIV patients from the Asia-Pacific region.
- Previous studies primarily focused on Western populations.
Purpose of the Study:
- To determine the prevalence of HBV and HCV coinfection among HIV patients in the Asia-Pacific.
- To evaluate the impact of coinfection on antiretroviral therapy (ART) response and mortality.
Main Methods:
- Utilized data from The TREAT Asia HIV Observational Database (TAHOD).
- Included patients tested for HBV surface antigen (HBsAg) or HCV antibody.
- Defined coinfection as any positive test for HBV or HCV.
Main Results:
- Prevalence of HBV and HCV coinfection was approximately 10% in the TAHOD cohort.
- Coinfection showed a non-significant trend towards lower CD4 count increase post-ART initiation.
- Neither HBV nor HCV coinfection was independently associated with increased mortality after covariate adjustment.
- Both HBV and HCV were independently associated with elevated alanine aminotransferase (ALT) levels.
Conclusions:
- The impact of HBV and HCV coinfection on ART response and HIV progression in this Asian cohort mirrors findings from Western studies.
- Longer-term monitoring is crucial to understand the full impact of hepatitis coinfection on HIV and liver disease outcomes.
Background And Aim:
Most studies of hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection with HIV have been conducted among Western patient populations. This study aims to assess rates of HBV and HCV coinfection, and their impact on response to antiretroviral therapy and mortality, using data from The TREAT Asia HIV Observational Database (TAHOD), a multi-center cohort of patients with HIV in the Asia-Pacific region.
Methods:
Patients who had been tested either HBV surface antigen (HBsAg) or HCV antibody were included. Patients who ever tested positive for HBV or HCV were regarded as coinfected for the duration of the study.
Results:
Results of hepatitis tests were available for 55% (HBV) and 49% (HCV) of 2979 TAHOD patients, with prevalence of HBV and HCV coinfection both at approximately 10%. Mean CD4 change at 180 days after antiretroviral treatment initiation was 118.8 cells/muL and patients with either HBV or HCV had a lower but non-significant CD4 increase compared with patients with HIV only. Median time to reach undetectable viral load (<400 copies/mL) was 148 days and was not independently associated with HBV or HCV. In univariate analysis, patients with HCV had increased mortality (unadjusted hazard ratio, HR 2.80, P = 0.007). However, neither HBV (adjusted HR 0.80, 95% confidence interval CI 0.24-2.64, P = 0.710) nor HCV (adjusted HR 1.06, 95% CI 0.40-2.79, P = 0.905) was associated with increased mortality after adjustment for other covariates. Both HBV and HCV remained independently associated with elevated alanine aminotransferase (ALT) in the multivariate model (HBV, adjusted HR 1.94, 95% CI 1.04-3.62, P = 0.037; HCV, adjusted HR 2.74, 95% CI 1.47-5.12, P = 0.002).
Conclusion:
The impact of hepatitis coinfection on immunological and virological responses to antiretroviral therapy and HIV disease progression among this Asian cohort are similar to that seen in Western countries. The longer-term impact of hepatitis coinfection on both HIV disease and liver disease morbidity and mortality needs to be monitored.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Retrovirus Life Cycles
Cryptococcal Meningitis

